MORGANTOWN, W. Va., April 14, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) announced today that the company's shares of common stock have commenced trading on the OTCQB marketplace of the OTC Markets Group Inc. under the ticker symbol PRGB.
"The commencement of trading represents an important milestone for our company," stated Steve Turner, Chief Executive Officer at Protea. "We anticipate that the initiation of trading will help us broaden our shareholder base, and increase awareness of our growing, global molecular information franchise. Protea serves large markets in pharmaceutical and life science research, and we look forward to highlighting our company to the global investment community."
More information on the company is available at: https://proteabio.com/investors
About Protea Biosciences Group, Inc.
Protea (OTCQB:PRGB) is a molecular information company, whose proprietary technology enables direct molecular imaging – the ability to identify and display biomolecules in tissue and cells, without sample pretreatment. Protea delivers robust molecular information to medical and life science researchers worldwide.
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the company's control. It is possible that the company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the company and its business, including factors that potentially could materially affect the company's financial results, are contained in the company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
CONTACT: Company Contact: Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26507 Phone: 304.292.2226 Fax: 304.292.7101 https://proteabio.com/investors email@example.com Investor Relations Contact: Jeff Ramson, ProActive Capital Group 646-863-6341 firstname.lastname@example.org
Source:Protea Biosciences, Inc.